Loading clinical trials...

Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease | Clinical Trials | Clareo Health

COMPLETEDNA

Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease

NCT03178786•NYU Langone Health

View on ClinicalTrials.gov

Summary

The purpose of this dual phase cross-sectional, controlled and prospective, open label, exploratory study is to determine the general characteristics of visuospatial exploration and its neural substrate in subjects with Parkinson's Disease (PD) and to explore the impact of professional art therapy intervention in a cohort of subjects with Parkinson's Disease on visuospatial exploration, visuomotor integration, neuropsychological and emotional sphere, quality of daily living and motor symptoms.

Eligibility

Age

40 - 75 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Diagnosis of PD according to United Kingdom Parkinson's Disease Society Brain Bank;
•Hoehn and Yahr stage 2 to 3;

Exclusion Criteria

•Exclusion Clinical Criteria (For both PD and Controls):
•History of dementia, or MoCA \< 22;
•Untreated depression, or score of \>20 on Beck Depression Inventory II;
•History of florid visual, tactile, olfactory or acoustic hallucinations requiring the administration of neuroleptics.
•Presence of psychosis requiring the administration of neuroleptics or sedatives.
•Presence of severe motor fluctuations with most of the 50% of day spent in off-time.
•Presence of bothersome dyskinesias.
•Presence of severe dystonia involving the head-neck axis including anterocollis, laterocollis and torticollis.
•Presence of severe fluctuations in attention, alertness or cognition.
•Presence of any clinically significant abnormality on vital signs.
+15 more criteria

Locations (1)

New York University School of Medicine

New York, New York, United States

Key Dates

Start Date

July 18, 2017

Primary Completion Date

January 30, 2020

Completion Date

August 10, 2020

Last Updated

March 21, 2022

Enrollment

ACTUAL participants

Conditions

Parkinson Disease

Interventions

PAT sessions

BEHAVIORAL

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

NCT06692920

Parkinson Disease

View study

RECRUITINGPHASE1

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 21, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease

Inclusion Criteria

Exclusion Criteria

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Montelukast in Parkinson Disease

Exercise for Cognitive Excellence in Parkinson's Disease

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients